Biotech "Tweets of the Week"
ASCO and Much More
(June 4-9, 2016)
Headlines - $ABBV $ADMP $ALXN $BIIB $CATB $DNAI $OCUL $SRPT $VBLT $VRX #ASCO16
In the News - $ACAD $AGIO $ALDR $CASC $EXEL $IMMU $NH $ONTY $PTI $RLYP $SAGE $TRIL $IBB $XBI #BIO2016
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Rapid-fire highlights of ASCO 2016
#ASCO16 Excited to hear the latest on immunotherapy and precision medicine in oncology. pic.twitter.com/i0PZq8tL45
— Feinstein Kean (@FKHealth) June 4, 2016
Impressive data from anti OX40 & PD-L1 phase I and anti CTL4 & PD-L1 phase 3. Future of immunotherapy is combination? #ASCO16 @Oncoinfo_it
— Carmelo Pozzo (@CarmeloPozzo) June 4, 2016
$abbv Rova-T results https://t.co/JY8B8tynC4
— Joe (@Drchik23) June 5, 2016
Daratumumab CASTOR looks great. 70% reduction in PFS progression, 19% vs 9% CR, 59% vs 29% PR. https://t.co/eJmQgOB5uj
— Brad Loncar (@bradloncar) June 5, 2016
AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors https://t.co/8V7IXP1Dnu [h/t @matthewherper]
— ENDPOINTS (@endpts) June 5, 2016
#ASCO16 Most exciting data so far from Ganymed's IMAB362, great news for #GastricCancer pts!https://t.co/JESqkz2IeA pic.twitter.com/nPlzh2OmEY
— Andy Biotech (@AndyBiotech) June 5, 2016
. @Adaptimmune thanks for the very clear & informative PR from #ASCO16 presentations - keep the open & unhyped tone! https://t.co/fQQPoHbXxs
— (((DieterHovekamp))) (@dhovekamp42) June 5, 2016
here comes a financial toxicity discussion (FAE) - "we can only afford true advances, not incremental advances"
— Paul D. Rennert (@PDRennert) June 5, 2016
cc: @adamfeuerstein
The curves for Darzalex in multiple myeloma are really impressive $JNJ $GEN pic.twitter.com/8xO0PBRkGx
— David Crow (@bydavidcrow) June 5, 2016
IMO this slide illustrates why you have to own a PD-L(1) to be a leader in oncology. $GILD $ABBV missing out. pic.twitter.com/41Byu7hxvQ
— Brad Loncar (@bradloncar) June 5, 2016
One of my favorite #ASC016 Sunday night activities: Reading sell-siders spin presented data to fit their pre-existing stock ratings.
— Adam Feuerstein (@adamfeuerstein) June 6, 2016
Genmab, which had already run a lot the last few weeks, is up another 2%+ on daratumumab. Your first #ASCO16 mover. pic.twitter.com/L10ZXbN9jd
— Brad Loncar (@bradloncar) June 6, 2016
@bradloncar Yeah- this may be year of cancer "small ball". Singles and doubles. But no doubt still plenty of progress.
— William Gerber (@WilliamGerber1) June 6, 2016
"We have reached an inflection point in the fight against cancer" @JoeBiden @asco2016 pic.twitter.com/ZfYEBZhROr
— Mace Rothenberg (@MaceRothenberg) June 6, 2016
VBL Therapeutics cashes in on questionable ASCO data release $VBLT
$VBLT
— Tom Wrigley (@WrigleyTom) June 6, 2016
VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Pl... https://t.co/BJ3lCKgqjr
$VBLT How do you trust a significant difference in survival between two dose levels of a drug in 15 patients?
— Matthew Herper (@matthewherper) June 6, 2016
$VBLT severe tox including 1 death, no mention at all todayhttps://t.co/3i78HbHMjb@JohnShaffer3 @MaverickNY @adamfeuerstein @matthewherper
— Andy Biotech (@AndyBiotech) June 6, 2016
Remember in 2014 when $VBLT was a public company for 6 days and then had to pull the offering? Ah, good times… https://t.co/CNtLS2ZFSN
— Adam Feuerstein (@adamfeuerstein) June 6, 2016
$VBLT strikes fast, registered direct 4.36M at $5.50
— zach (@zbiotech) June 7, 2016
I spoke w/ a buyer of the $VBLT offering. He’s out already. Buys in at nice discount, sells to you for quick profit. That’s how game works.
— Adam Feuerstein (@adamfeuerstein) June 7, 2016
Right now $VBLT is enjoying the "those guys pulled off a pretty good scam" premium. Look out below with the next pullback.
— Tony Friedman (@zzlangerhans) June 7, 2016
Bad news hides in ASCO's shadow $ADMP $ALXN $BIIB $CATB $DNAI $OCUL
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine $admp https://t.co/05OMbhxpaJ
— AstroFrog (@Chemistfrog) June 6, 2016
$DNAI Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL. #Fail
— Bio Stocks™ (@BioStocks) June 6, 2016
$DNAI a good tell for this data was when they licensed a back-up drug last weekhttps://t.co/UGyoEVExJA
— Andy Biotech (@AndyBiotech) June 6, 2016
Ocular’s Shares Fall After Eye Treatment Fails Latest Test https://t.co/7xxyBNNmkp $OCUL
— Ben Fidler (@BentheFidler) June 6, 2016
$DNAI ↓ 52% , $OCUL ↓ 41% , $ADMP ↓ 45% PM
— Bio Stocks™ (@BioStocks) June 6, 2016
$ALXN says Soliris misses primary goal in refractory generalized myasthenia gravis study; shares halted, call 5pmET https://t.co/g5Po10cX00
— Meg Tirrell (@megtirrell) June 6, 2016
$BIIB Anti-LINGO Ph2 MS trial #FAIL https://t.co/CL5JIrWhKf
— Andy Biotech (@AndyBiotech) June 7, 2016
Bummer on $BIIB LINGO. One of those things that could have boosted the mood of the whole sector if it had worked.
— Brad Loncar (@bradloncar) June 7, 2016
@JMac_SI Buyside was pretty much 50/50 on this p2 - no-one really had a clue what to expect
— Red Acre Investments (@redacre) June 7, 2016
GS $BIIB OUCH remove Opicinumab estimates from model (previously peak sales of $6bn at 20% probability of success)price target 267 from $285
— dough (@tgtxdough) June 7, 2016
$CATB In this day+age wheb a bio wants to, but cannot lower LDLc, rest of pipeline cannot be worth anything: https://t.co/2uSvnL8GcX
— Dirk Haussecker (@RNAiAnalyst) June 7, 2016
Sarepta plot takes one more twist $SRPT
$SRPT Sarepta Therapeutics Says FDA Requests Dystrophin Data
— BioBreakout (@BioBreakout) June 6, 2016
$SRPT up 28% after hrs on announcing FDA asked for dystrophin data from ongoing confirmatory study https://t.co/HvchZBL98z
— Meg Tirrell (@megtirrell) June 6, 2016
Would $SRPT be kind enough to share with investors such dystrophin data along with its submission to FDA? Kinda material info I'd say.
— (((BiotechSage))) (@BiotechSage) June 6, 2016
It's official: I'm lost $SRPT.
— Abby Nachtomi (@anachtomi) June 7, 2016
$SRPT , FDA Compromise on Plan to Secure Duchenne Drug Approval https://t.co/56QrvBvFuG via @TheStreet
— Adam Feuerstein (@adamfeuerstein) June 7, 2016
@matthewherper "Fans of the stock are right that the odds of approval just went up – but nobody knows from what to what." Great point. $srpt
— 23aloha (@23aloha) June 7, 2016
. @BiotechBbqBeats @matthewherper Bulls & bears should be happy w/ FDA $SRPT compromise. Eteplirsen dystrophin data will decide approval.
— Adam Feuerstein (@adamfeuerstein) June 7, 2016
$SRPT secondary ~$38M raise
— zach (@zbiotech) June 8, 2016
$SRPT is up 9.5% after the financing PR. on a huge 7.7M shares volume in 1.5 hours pic.twitter.com/qkcroI0LHc
— Joe (@GantosJ) June 9, 2016
@fierro7676 @Val_Invest_12 NOBODY I mean nobody has came close to predicting anything with accuracy on $SRPT been a crapshoot last year
— dough (@tgtxdough) June 9, 2016
$SRPT with record high volume for the 3rd day in a row. Over 10 M in each round
— Bursatil Biotech (@BursatilBiotech) June 9, 2016
Valeant sinks again on yet another cut in guidance $VRX
$VRX - one year ago the street saw EBITDA at $8.4bn. Today Valeant is telling us 2016 EBITDA could hit $4.95bn at best. #MeltingIceCube
— Angry Arb (@AngryArb) June 7, 2016
Why is Valeant missing earnings a surprise? Of course Papa was going to clear the decks for himself. $VRX https://t.co/Kk8aZGRVL2
— Downtown Josh Brown (@ReformedBroker) June 7, 2016
$VRX CEO Papa says: "We have a solid position with our liquidity, and I expect to be in compliance with our debt covenants in 2016"
— Jonathan Rockoff (@jonathanrockoff) June 7, 2016
So you have a GAAP forecast but don't want to share it???????? $VRX
— Charley Grant (@CGrantWSJ) June 7, 2016
For those keeping track at home, Valeant's market cap is down about $1.92 billion from yesterday to today's open.
— Drew Armstrong (@ArmstrongDrew) June 7, 2016
$VRX PT cut to $17-$22 at Wells Fargo
— Bio Stocks™ (@BioStocks) June 8, 2016
deal was so fantastic...trying to restructure 6m in? $VRX $WBA
— zach (@zbiotech) June 8, 2016
As seen on the stream
BioPharmCatalyst FDA Calendar https://t.co/DWxRfvxyfl & Company Pipeline Database https://t.co/h90BnmiIkd fully updated post 1Q 10Qs.
— BioPharmCatalyst (@crusadernz) June 6, 2016
Some nHod$IBB $BIB $XBI $GILD $AMGN$PBYI $MYL $ICPT $ACAD $ALNY$KITE $JUNO $BLUE $NVCR $VBLT$RDUS $CELG $VRTX $CYCC $CLVS
— Tom Wrigley (@WrigleyTom) June 6, 2016
that deal $GILD should've done? $BMY
— zach (@zbiotech) June 6, 2016
@mikegoodma they won't make a run at first line until #NCCN guidelines puts them there. They have their hands full w/ OPDIVO in second-line!
— Sheff (@SheffStation) June 6, 2016
$IBB $XBI Headfake this morning
— Jake King (@FajaJake) June 6, 2016
@ohmsonite @23aloha $PTI is interesting. I'll go into it more when I have more time.
— Michael Torres, PhD (@Mykalt45) June 6, 2016
Judge rules $GILD not liable for $200m damages + royalties for SOF patent infringement as $MRK attorney gave "untruthful testimony" #HCV
— Michael Haydock (@datamonitor_MH) June 7, 2016
$ALXN removed from US 1 List at BofA/Merrill
— Bio Stocks™ (@BioStocks) June 7, 2016
All covered in $TTNP from 7.30-7.50 average. Biggest trade for me so far. Pic coming tomorrow.
— Brice Foose (@PharmDFoose) June 7, 2016
NantHealth $NH making a new low, now with a $15 handle, who knows what could be going on... ¯\_(ツ)_/¯ pic.twitter.com/EIwyXTRw58
— Jean Fonteneau (@JFinDallas) June 7, 2016
$NH already on the short restriction list only 2 days into it's existence, quite the performance...
— Jean Fonteneau (@JFinDallas) June 7, 2016
Took a starter in $rvnc today. Was trying for days. Got tired of watching it rise every day without me. Data due soon.
— Joe (@Drchik23) June 7, 2016
@WilliamGerber1 Array's done a great job of creating wealth for shareholders--just not theirs :)
— Year of Glad (@pemulisking) June 7, 2016
$tril cd47 mention: ASCO 2016 Update: Beyond Checkpoint Blockade: Novel Immunotherapy Strategies for Solid Cancers - https://t.co/IDl5YDE6kL
— Boaty McBoatface (@srqstockpicker) June 7, 2016
$RVNC bucking biotech sell-off; shares at 3-month high.
— Roy Friedman (@DewDiligence) June 7, 2016
$SAGE $MRNS pic.twitter.com/fh9WZVOgbW
— CNS Investing (@CNS_Investing) June 7, 2016
@BioBounce take the money and run
— Festo (@Festo50) June 7, 2016
"I want to go on the record -- I think that Sovaldi was underpriced for what it does."
— Matthew Murphy (@murphym45) June 7, 2016
-Mark Alles, Celgene CEO#BIO2016 $CELG $GILD
Mental Disorders Top The List Of The Most Costly Conditions In The United States: $201B https://t.co/1FOn1nA62b pic.twitter.com/VZi5lbC5iA
— Andy Biotech (@AndyBiotech) June 8, 2016
"Sanofi believes that Medivation's shareholders overwhelmingly support the sale of Medivation" no, not to $SNY - run away fast!
— Sally Church (@MaverickNY) June 8, 2016
$ACAD up 14% from Friday after hours session.
— BioBounce.com (@BioBounce) June 8, 2016
$ONTY (Oncothyreon) changes name to Cascadian Therapeutics and ticker to $CASC as it switches gears from therapeutic vaccines to cancer
— Lisa LaMotta (@BioWriterChik) June 8, 2016
$ACAD..$41.90 great run from $36 last week on buyout/takeover rumors. Let's see what Julian Baker has up his sleeves.
— Sheff (@SheffStation) June 8, 2016
Amused to see Newt embraced at #BIO2016, promoting his book. While in Congress, he once wanted to abolish the FDA.
— Luke Timmerman (@ldtimmerman) June 8, 2016
Big hat tip to @AndyBiotech RT @cardiobrief: First PCSK9 Outcome Trial Results Pushed Back To 2017 https://t.co/mFJwU6CiCT
— Larry Husten (@cardiobrief) June 8, 2016
. @JimGreenwood Jim, you can’t blame insurance cos. for everything. Take responsibility for your part in unsustainable drug price practices.
— Adam Feuerstein (@adamfeuerstein) June 8, 2016
@Pharmdca @Lin_ling_88 lack of patience has both saved me $ & cost me money. I think it's a wash. Have to know when to trust your research.
— Adam Singer (@AdamSinger) June 8, 2016
$KMPH Files NDA Amendment Request with FDA for Apadaz https://t.co/Q5VmPnoIVA
— Bio Stocks™ (@BioStocks) June 9, 2016
@lipscrl these are short term targets, still think we go much higher after another pb
— Randy (@lipscrl) June 9, 2016
$ONCE CC on Monday June 13 at 8:30am to Discuss SPK-9001 PH 1/2 Data for the Treatment of Hemophilia B #EHA16 https://t.co/9CLKa0HKSp
— Odi (@odibro) June 9, 2016
$ARWR 2nd HBV drug in humans dosing now, NOT CHIMPS.
— avidresearch (@avidresearch) June 9, 2016
$ALDR
— S Manian (@DrSManian) June 9, 2016
"data support a quarterly, single injection dosing strategy with ALD403" https://t.co/Yx1mzxHrVt
Congrats to @AKAarsalan and @JohnCBiotech - look forward to seeing the next iteration of @endpts
— Andrew G. (@BioDueDiligence) June 9, 2016
$RLYP back over 50 day SMA due to medical/KOL facts! Not MS BS!
— HumbleBioTrader (@HumbleBioTrader) June 9, 2016
dueling rumors on $RLYP this morning.
— David Sobek (@dsobek) June 9, 2016
Hahaha $immu. I love vacations.
— DeadCatBill (@getbillasap) June 9, 2016
@exMBB desperate+ frustration
— Pharm. D (@Pharmdca) June 9, 2016
$IMMU blood bath continues! Down 42% since the fiasco started
— Shane Blackmon (@shaneblackmon) June 9, 2016
$AGIO up 6 bucks yesterday down 10 today. $IBB never a dull moment for sure
— dough (@tgtxdough) June 9, 2016
Funny day…$INSM barely down w 2yr delay to mkt
— Andy Biotech (@AndyBiotech) June 9, 2016
While $SCYX -20% on some nice PoC data showing drug clearly activehttps://t.co/659hhAa9LW
I Sold 1/2 $fmi & 3/4 $aldr (prior to data). Only holding $rvnc through data currently. By weight: $fmi 9%; $egrx 5%; $rlyp 5% $rvnc 5%
— Joe (@Drchik23) June 9, 2016
$BIIB loses $6B in value with LINGO failure. Context: that's just shy of value of all of the VC funding into biotech in 2015, into 500 co's
— Bruce Booth (@LifeSciVC) June 7, 2016